logo
Natural selection for greener cleaning products?

Natural selection for greener cleaning products?

An INRS study based on natural selection is paving the way for very promising advances in biosurfactants.
LAVAL, QC, April 3, 2025 /CNW/ - Produced biologically using bacteria, these 'natural soaps' are a more environmentally friendly, less irritating and non-toxic alternative to synthetic surfactants derived from petrochemical processes, which are found in most soaps, detergents, shampoos, etc. However, the inadequate performance of the bacteria that produce them and the very high cost of production remain major development and marketing hurdles.
Natural selection to increase the production of secondary metabolites: a first
Professor Eric Déziel, an expert in microbiology and bacterial multicellularity, has long been interested in these biosurfactants and is a pioneer in this field. He wants to improve the production of these bacteria-based 'natural soaps' and make their use widespread. Together with his team, he recently developed a novel Adaptive Laboratory Evolution (ALE) procedure, a directed evolution method based on natural selection (darwinism), to improve the productivity of biosurfactants. It is the subject of the article 'Implementation of an adaptive laboratory evolution strategy for improved production of valuable microbial secondary metabolites' recently published in Bioresource Technology.
The laboratory, which is specialized in sociomicrobiology (social behaviour of bacteria), is the first to use such a strategy to increase the production of so-called 'secondary' metabolites, here biosurfactants, using bacteria. This is exceptional since ALE strategies, which are based on a 'fitness' advantage, are normally used to improve essential organism traits. However, the biosurfactants studied here are not crucial to bacteria survival.
'Using natural selection to increase the production of secondary metabolites, in this case biosurfactants, provides a unique perspective in the field of biotechnology. This will enable new bioprocesses to be developed to valorize wastes and replace chemicals. This is very promising for the bioeconomy since it is based on the performance of bacteria, not their growth, as in traditional methods.'
Professor Eric Déziel, INRS microbiologist
A promising new bacterium being studied
For this study, Professor Déziel's team, based at the INRS Armand-Frappier Santé Biotechnologie Research Centre, used a new biosurfactant-producing bacterium named Burkholderia thailandensis. The bacterium does not pose a risk to humans, contrary to Pseudomonas aeruginosa, which is generally used for the commercial production of rhamnolipids, one of the two main biosurfactants currently available on the market. The 'swarming' type of social motility expressed by B. thailandensis in order to effectively colonize its environment requires the production of rhamnolipids. These 'soaps' act as motility facilitators by wetting the surface and reducing surface tension and friction.
When growing bacteria in the laboratory, microbiologists use agar as a gelling agent for nutrient media. The research team hypothesized that an increase in agar levels during swarming experiments would force cells to produce more surfactants to move more easily over the surface. Consecutive cycles of B. thailandensis cultures on swarming media achieved with increasing concentrations of agar indeed increased the production of rhamnolipids, with the surfactants acting as a wetting agent, by evolved populations.
In addition, the study of these evolved bacterial populations has identified a previously unknown protein, QsmR, which acts as a suppressor of rhamnolipid production. This is an unexpected discovery that promises further advances in the production of biosurfactants by Burkholderia bacteria.
Paving the way to sustainable biotechnology
The natural selection experimental strategy developed by Professor Déziel's team could be used by researchers to improve the performance of new producing bacteria. This would increase the variety of 'natural soaps' available to meet different consumer needs and thus make this sustainable alternative to chemicals more widely available.
It could represent a revolution in the field, since surfactants, ingredients widely used in cleaning, personal care and pharmaceutical products, currently represent a market of more than $50 billion. The industry has already expressed its interest in this innovative methodology to Professor Déziel.
About the study
The article 'Implementation of an adaptive laboratory evolution strategy for improved production of valuable microbial secondary metabolites' by Sarah Martinez, David N. Bernard, Marie-Christine Groleau, Mylène C. Trottier and Eric Déziel, was published in Bioresource Technology on March 4, 2025.
'Participating in this innovative project was an enriching experience for my doctorate, driven by the curiosity to apply a simple but bold idea, knowing that it would have an impact on the future of research into biosurfactants. Working on the basis of the principles of natural selection allows us to free ourselves from GMO concepts, which can sometimes be poorly regarded in biotechnology, thus offering new study perspectives.'
PhD graduate Sarah Martinez, INRS
This research was funded by the Natural Sciences and Engineering Research Council of Canada, with the support of the Armand-Frappier Foundation.
About INRS
INRS is an academic institution dedicated exclusively to graduate research and training in strategic sectors in Quebec. For the past 55 years, it has actively contributed to Quebec's economic, social, and cultural development. INRS is first in Canada in research intensity. It is made up of four interdisciplinary research and training centres located in Quebec City, Montreal, Laval, and Varennes, which focus their efforts on strategic sectors: water, earth, and environment ( Eau Terre Environnement Research Centre); energy, materials, and telecommunications ( Énergie Matériaux Télécommunications Research Centre); urbanization, culture, and society ( Urbanisation Culture Société Research Centre); and health and biotechnology ( Armand-Frappier Santé Biotechnologie Research Centre). The INRS community includes over 1,500 students, postdoctoral fellows, and faculty and staff members.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS CLARUS 700 Receives NMPA Approval in China

Yahoo

time13 hours ago

  • Yahoo

ZEISS CLARUS 700 Receives NMPA Approval in China

ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation. "ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow." "Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China. Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them. More information about the CLARUS® 700 from ZEISS can be found here. 1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: View original content to download multimedia: SOURCE Carl Zeiss Meditec AG View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS CLARUS 700 Receives NMPA Approval in China

Yahoo

time13 hours ago

  • Yahoo

ZEISS CLARUS 700 Receives NMPA Approval in China

ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation. "ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow." "Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China. Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them. More information about the CLARUS® 700 from ZEISS can be found here. 1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: View original content to download multimedia: SOURCE Carl Zeiss Meditec AG View original content to download multimedia:

New Genomics Investments Expand eDNA Monitoring in BC's Remote and Indigenous Communities
New Genomics Investments Expand eDNA Monitoring in BC's Remote and Indigenous Communities

Yahoo

time20 hours ago

  • Yahoo

New Genomics Investments Expand eDNA Monitoring in BC's Remote and Indigenous Communities

VANCOUVER, BC, June 5, 2025 /CNW/ - On World Environment Day, Genome British Columbia (Genome BC) is proud to announce significant new investments that will expand Canada's capacity for environmental DNA or RNA (collectively called 'eDNA') monitoring. These investments highlight British Columbia's leadership in leveraging genomics to address pressing environmental and health challenges, particularly in remote and Indigenous communities. Nature's Fingerprints: eDNA is a New Tool that Reveals What's Living Around Us eDNA is a powerful tool that uses trace genetic material left behind in water, air and soil to detect pathogens, assess ecosystem health and support environmental decision-making. eDNA allows scientists and communities to detect and track species without needing to see them directly, offering a more efficient way to study ecosystems. eDNA can also track health and ecological signals without relying on invasive testing. This technology was widely used during the COVID-19 pandemic to monitor virus levels in wastewater and is now being expanded to keep people safe, protect biodiversity and help with climate resilience. The projects announced today focus on ensuring these tools are not just scientifically robust, but also community-driven and accessible — especially for regions with limited existing monitoring infrastructure. "These investments reflect how genomics is helping us learn directly from the environments we live in — and how that knowledge can be shared in ways that empower communities," said Federica Di Palma, Chief Scientific Officer and Vice President, Research and Innovation at Genome BC. "By supporting eDNA research rooted in partnership with Indigenous and remote communities, BC researchers are helping lead the way toward more inclusive, real-time approaches to health and environmental monitoring." Three Projects Expanding eDNA Use and Data Sharing The ChùNet and iMicroSeq projects are BC-based projects awarded through Genome Canada's eDNA Surveillance program, which includes a $11.3 million investment in 12 projects across the country aimed at building the scientific, technical and community capacity needed to scale eDNA surveillance. The eDNA Explorer Canada project is a separate initiative funded by Genome BC, though all three projects will coordinate their efforts. ChùNet: Enabling a knowledge sharing network — learning from water and the life it carries Led by: Erin Gill (Simon Fraser University) and Math'ieya Alatini (One Yukon Coalition) This project will establish a community-focused network to share data and knowledge about water-based eDNA monitoring in northern, rural, remote and Indigenous communities in BC and the Yukon. Co-led by academic and community partners, ChùNet will create tailored training resources and deploy a demonstration monitoring project while respecting OCAP® principles. The aim is to build a wholistic foundation for integrating environmental and public health surveillance that builds local priorities into decision making. iMicroSeq: Integrated, inclusive resources supporting environmental sequence data Led by: Fiona Brinkman and Emma Griffiths (Simon Fraser University) This project will develop a national data portal and communications platform that brings together researchers, Indigenous communities, public health officials and other in industry to support more coordinated, integrated microbial eDNA monitoring for wastewater and other water data. iMicroSeq will enhance data sharing, respect Indigenous data sovereignty (CARE and OCAP® Principles), and link human, agricultural and environmental health through a One Health lens. The platform will empower both community and industry innovation in economic, water-based pathogen detection and climate resilience. eDNA Explorer Canada: Upscaling eDNA Explorer to Enable Effective Biodiversity Monitoring in Canada Led by: Caren Helbing (University of Victoria) and Rachel Meyer (University of Santa Cruz & Chief Scientific Officer at eDNA Explorer) This project leverages the eDNA Explorer platform developed in California to create eDNA Explorer Canada. This powerful, easy-to-use portal will allow anyone to understand, evaluate and share eDNA data gathered in Canadian ecosystems, focusing on biodiversity monitoring, conservation and restoration. eDNA Explorer Canada is tailored to meet Canadian environmental standards and sovereignty needs, ensuring data is reliable and legally compliant. It aims to turn raw data into actionable insights that drive environmental protection efforts, building on existing relationships with Indigenous and government agencies established through the iTrackDNA project, which in 2021 and 2023 established Canada's national eDNA standards (learn more about those standards here). About Genome British Columbia: Genome BC is a not-for-profit organization that has advanced genomics research and innovation for 25 years, growing a world-class life sciences sector in BC and delivering sustainable benefits for British Columbia, Canada and beyond. Genome BC has attracted over $1 billion in direct co-investment to the province, which has contributed to funding more than 550 genomics research and innovation projects. These initiatives enhance healthcare and address environmental and natural resource challenges, improving the lives of British Columbians. Genome BC also integrates genomics into society by supporting responsible research and innovation and fostering an understanding and appreciation of the life sciences among educators, students and the public. SOURCE Genome British Columbia View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store